

Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study

International Journal of Stroke
2023, Vol. 18(10) 1219–1227
© 2023 World Stroke Organization



Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/17474930231181010
journals.sagepub.com/home/wso



Elisavet Moutzouri^{1,2,3} , Matthias Glutz¹, Nazanin Abolhassani^{1,4}, Martin Feller¹ , Luise Adam¹, Baris Gencer^{1,5}, Cinzia Del Giovane¹, Sylvain Bétrisey¹, Rebecca E Paladini⁶, Elisa Hennings^{6,7} , Stefanie Aeschbacher^{6,7}, Jürg H Beer⁸, Giorgio Moschovitis⁹, David Seiffge¹⁰, Gian Marco De Marchis¹¹, Michael Coslovsky^{6,12}, Tobias Reichlin¹³, Giulio Conte¹⁴, Tim Sinnecker¹¹, Matthias Schwenkglens^{15,16}, Leo H Bonati¹¹, Peter Kastner¹⁷, Drahomir Aujesky^{1,2}, Michael Kühne^{6,7}, Stefan Osswald^{6,7}, Urs Fischer^{10,11} , David Conen^{13,18} and Nicolas Rodondi^{1,2}; on behalf of the Swiss-AF Investigators

Abstract

Background: An increased risk of intracranial hemorrhage (ICH) associated with statins has been reported, but data on the relationship between statin use and cerebral microbleeds (CMBs) in patients with atrial fibrillation (AF), a population at high bleeding and cardiovascular risk, are lacking.

Aims: To explore the association between statin use and blood lipid levels with the prevalence and progression of CMBs in patients with AF with a particular focus on anticoagulated patients.

Methods: Data of Swiss-AF, a prospective cohort of patients with established AF, were analyzed. Statin use was assessed during baseline and throughout follow-up. Lipid values were measured at baseline. CMBs were assessed using magnetic

¹Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

²Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

³Department of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

⁴Department of Epidemiology and Health Systems, Center for Primary Care and Public Health, (Unisanté), University of Lausanne, Lausanne, Switzerland

⁵Department of Cardiology, HUG, University Hospital Geneva, Geneva, Switzerland

⁶Cardiovascular Research Institute Basel, Basel University Hospital, University of Basel, Basel, Switzerland

⁷Cardiology Division, Department of Medicine, Basel University Hospital, University of Basel, Basel, Switzerland

⁸Department of Medicine, Cantonal Hospital of Baden and Center for Molecular Cardiology, University Hospital of Zurich, Zurich, Switzerland

⁹Cardiology Division, Regional Hospital of Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland

¹⁰Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

¹¹Department of Neurology and Stroke Center, Basel University Hospital, University of Basel, Basel, Switzerland

¹²Department Clinical Research, Basel University Hospital, University of Basel, Basel, Switzerland

¹³Division of Cardiology, Department of Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

¹⁴Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland

¹⁵Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland

¹⁶Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland

¹⁷Roche Diagnostics GmbH, Penzberg, Germany

¹⁸Population Health Research Institute, McMaster University, Hamilton, ON, Canada

Corresponding author:

Elisavet Moutzouri, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
Email: elisavet.moutzouri@extern.insel.ch

resonance imaging (MRI) at baseline and at 2 years follow-up. Imaging data were centrally assessed by blinded investigators. Associations of statin use and low-density lipoprotein (LDL) levels with CMB prevalence at baseline or CMB progression (at least one additional or new CMB on follow-up MRI at 2 years compared with baseline) were assessed using logistic regression models; the association with ICH was assessed using flexible parametric survival models. Models were adjusted for hypertension, smoking, body mass index, diabetes, stroke/transient ischemic attack, coronary heart disease, antiplatelet use, anticoagulant use, and education.

Results: Of the 1693 patients with CMB data at baseline MRI (mean \pm SD age 72.5 ± 8.4 years, 27.6% women, 90.1% on oral anticoagulants), 802 patients (47.4%) were statin users. The multivariable adjusted odds ratio (adjOR) for CMBs prevalence at baseline for statin users was 1.10 (95% CI = 0.83–1.45). AdjOR for 1 unit increase in LDL levels was 0.95 (95% CI = 0.82–1.10). At 2 years, 1188 patients had follow-up MRI. CMBs progression was observed in 44 (8.0%) statin users and 47 (7.4%) non-statin users. Of these patients, 64 (70.3%) developed a single new CMB, 14 (15.4%) developed 2 CMBs, and 13 developed more than 3 CMBs. The multivariable adjOR for statin users was 1.09 (95% CI = 0.66–1.80). There was no association between LDL levels and CMB progression (adjOR 1.02, 95% CI = 0.79–1.32). At follow-up 14 (1.2%) statin users had ICH versus 16 (1.3%) non-users. The age and sex adjusted hazard ratio (adjHR) was 0.75 (95% CI = 0.36–1.55). The results remained robust in sensitivity analyses excluding participants without anticoagulants.

Conclusions: In this prospective cohort of patients with AF, a population at increased hemorrhagic risk due to anticoagulation, the use of statins was not associated with an increased risk of CMBs.

Keywords

Cerebral hemorrhage, lipid levels, cerebral microbleeds, statin use, brain bleed, brain microbleeds

Received: 8 February 2023; accepted: 2 May 2023

Introduction

Intracranial hemorrhage (ICH) accounts for approximately 10–20% of all strokes and is associated with high mortality and disability.¹ In the Treat Stroke to Target Trial the number of ICH events was higher in patients with lower target LDL levels.² An increased risk of ICH associated with statins and low cholesterol levels is supported by other studies,^{3,4} but these associations remain controversial.^{5–7}

Cerebral microbleeds (CMBs) are hypointense lesions on T2-weighted gradient-echo magnetic resonance imaging (MRI). They are considered to be an asymptomatic precursor of ICH, especially in patients with a high burden of CMBs,^{8,9} while they are also associated with an increased risk for ischemic stroke.⁸ Few studies have examined the association of statin use and lipid levels with the presence of CMBs, and very few with the progression of CMBs, with conflicting results.^{10–13} These studies had several limitations, including small sample sizes, heterogeneous MRI protocols with lack of blinded assessment, and limitations regarding adjustment for important covariates, potentially explaining the conflicting results.

Patients with atrial fibrillation (AF) is a population at potential increased bleeding risk due to oral anticoagulation.^{14–16} The prevalence of CMBs may in fact be significantly higher in patients with AF than in those without AF.^{14,16} However, AF patients are also at increased cardiovascular risk and treatment with statins is often indicated.¹⁶ Thus, a possible association between statins or blood lipid

levels with CMBs may have therapeutic implications also in terms of identifying modifiable risk factors for CMBs in AF patients.

The aim of this prospective, observational, study was to investigate for the first time the association of statin use and lipid levels with the presence and progression of CMBs in the AF population.

Method

Swiss-AF

Swiss-AF is an ongoing prospective multicenter observational cohort study conducted in 14 centers in Switzerland, which enrolled 2415 participants. The main protocol has been described elsewhere.¹⁷ Details about inclusion/exclusion criteria, recruiting centers, MRI protocol, and laboratory measurements are reported in the supplemental material.

Outcomes and aims

Primary outcomes: (1a) CMBs at baseline (none or ≥ 1) and (1b) CMBs progression (defined as at least one additional or new CMB on follow-up MRI at 2 years compared with baseline MRI).

Secondary outcome: ICH (excluding subarachnoid hemorrhage and subdural hematoma) during follow-up. ICH was defined according to the International Society on

Thrombosis and Hemostasis criteria and was independently adjudicated according to the Swiss-AF main protocol.^{17,18}

Primary aim: to investigate the association between statin exposure, defined as yes or no at baseline and outcomes as described above. The secondary aim focused on the association of the abovementioned primary outcomes with blood lipid levels (primarily low-density lipoprotein (LDL) but also total cholesterol (TCHOL), triglycerides (TRG), and high-density lipoprotein (HDL)) at baseline as continuous variables.

Statistical analysis

Baseline characteristics are presented separately for statin users (participants with any statin use at baseline) and non-users. Association of statin use or lipid levels (TCHOL, LDL-C, HDL-C, and TRG separately, each as a continuous variable per 1-unit increase) with the prevalence of CMBs at baseline, as well as the progression of CMBs at follow-up, was assessed using logistic regression models. The results are presented as odds ratios (OR, 95% confidence intervals (CI)). For the occurrence of ICH during follow-up, we used flexible parametric survival models. The results are presented as hazard ratios (HR) with 95% CI.¹⁹ All analyses were adjusted for confounding factors potentially associated with both the exposure (statin and blood lipid levels) and the outcome (CMBs) using directed acyclic graph (DAG) models based on prior knowledge of association with CMBs: sex, age, history of hypertension, smoking status, body mass index (BMI), history of diabetes, history of stroke or transient ischemic attack (TIA), coronary heart disease, antiplatelet use, anticoagulant use, and education. Due to the low number of events, flexible parametric survival models for ICH were only adjusted for sex and age.

In the main analysis, participants were categorized as follows: baseline statin use versus no use. Further analyses were done for high-dose baseline use versus low- and medium-dose use versus no use (high, medium, low statin doses as defined from ACC/AHA).²⁰ All medications were assessed at baseline and at years 1 and 2. We performed time-updated sensitivity analyses by change in statin (stop/start) and change in statin intensity during follow-up.

Supplemental analyses were performed focusing on lobar CMBs, based on previous observations suggesting that statin and LDL levels might be primarily associated with a higher bleeding risk in the lobar brain regions.²¹ Additional analyses were performed by restricting the investigation to patients under oral anticoagulants.

Power calculation is reported in the supplemental material. All data analyses were carried out using STATA version 16.0. No correction was performed for multiple testing. The study is reported following the STROBE guidelines for cohort studies.²²

Results

Patients characteristics


Of the 2415 patients enrolled in Swiss-AF, 667 did not have brain MRI at baseline. The main reason for a missing brain MRI was the presence of a cardiac device (N=461, 69%). Other reasons included further contraindications to perform an MRI or claustrophobia of the patient. Fifty-five patients had brain MRI without CMB data. A total of 1693 (468 [27.6%] females, mean [SD] age 72.5 years [8.4], 90.1% under oral anticoagulants) having CMB data at baseline MRI were included (Figure 1).²³ Statin users (N=802) had more hypertension (79.7% vs 59.9%), more diabetes (23.6% vs 8.6%), more often a history of stroke/TIA (29.1% vs 11.1%), and other known cardiovascular disease (44.4% vs 9.2%). The percentage of patients under oral anticoagulation was 92.1% in the statin and 88.3% in the non-statin user group. The use of vitamin K antagonist (VKA) compared with direct oral anticoagulants (DOACs) was higher under statin users (Table 1). The cohort represented an intermediate bleeding risk population.²⁴ A total of 72% of statin users versus 74% of non-statin users had 3.0T scanner.

At 2 years, 1188 of the 1693 identified patients had follow-up MRI (Figure 1). The reasons for declining 2 years MRI included the following: the patient developed contraindications for MRI (e.g. pacemaker), patient was no longer able to come to the hospital on his own (follow-up visit carried out by telephone), patient developed claustrophobia or had unpleasant experience from MRI at baseline, patient did not want to come for other reasons, and patient withdrew or was deceased. For example, at the study site of Bern (N=368), a telephone visit was performed in 15% of the participants at 2 years follow-up. Eighty (3.3%) patients had no 2-year follow-up visit.¹⁵ The characteristics of patients who had baseline and follow-up MRI were comparable (Supplemental Tables S1 and S2).

Cross-sectional analysis

At baseline, 213 (26.5%) statin users and 163 (18.3%) non-statin users were found to have at least one CMB. After adjustment for history of hypertension, smoking status, BMI, history of diabetes, history of stroke or TIA, coronary heart disease, antiplatelet use, anticoagulant use, and education no significant association was observed (adjOR, 1.10 (95% CI = 0.83–1.45)) (Table 2). Similar were the results for lipid levels (Supplemental Table S3). Covariates' association with CMBs prevalence is shown in Supplemental Table S4. No association for lobar CMBs at baseline was observed, neither for statin use (Table 2) nor for LDL levels (Supplemental Table S5). Also, no association was observed by restricting the analysis to patients under oral anticoagulants (Supplemental Table S6).

Figure 1. Flow chart of participant selection.



Longitudinal analysis

At 2 years, follow-up progression of CMBs was observed in 44 (8.0%) patients in the statin group and 47 (7.4%) patients in the non-statin group, respectively. Of the 91 patients who developed new CMBs, 64 (70.3%) developed a single new CMB, 14 (15.4%) developed 2 CMBs, and 13 participants developed more than 3 CMBs. In all, 42 patients had strictly lobar CMB progression, 16 had deep CMB progression, and 14 had infratentorial CMB progression. The remaining patients (N=19) had CMB progression in mixed locations.

No association between statin use and CMB progression was observed in the multivariable logistic regression model (adjOR, 1.09 (95% CI = 0.66–1.80)) (Table 3). There was also no statistically significant association between blood lipid levels and CMB progression (Supplemental Table S3). Univariable association of covariates with CMB progression at follow-up is presented in Supplemental Table S7. The total number of patients having progression of lobar CMBs was 57 (35 statin users and 22 non-statin users). In multivariable adjusted models, no association could be seen for statin use (Table 3) or LDL levels (Supplemental Table S5) with lobar CMBs progression.

By restricting the analysis to patients under oral anticoagulants, a total of 84 patients having CMBs progression was observed. No association could be seen either for statin use, or for LDL levels (Supplemental Table S6).

Our results remained robust in sensitivity analyses, adjusting for new statin introduction or increase in intensity or by classifying statins as low, medium or high intensity (Supplemental Table S8).

The number of ICH observed during follow-up was low in both groups, with a total of 14 events in the statin users and 16 in the non-statin users, showing no hazard difference between the two groups in the age and sex adjusted model (adjHR, 0.75, 95% CI = 0.36–1.55; Supplemental Table S9).

Discussion

In this large prospective cohort study of older persons with AF, we found no evidence that statin use or lipid levels are associated with CMBs prevalence or with CMBs progression at 2 years follow-up. To our knowledge, this is the largest and longest prospective cohort study reporting on these outcomes. This study is particularly relevant since >90% of participants were on anticoagulation, with robust results even after excluding 9.6% of patients, who were not anticoagulated.

A recent meta-analysis also observed a positive association of statin use with the prevalence of all and lobar CMBs in unadjusted, but not in fully adjusted models.²⁵ However, the same meta-analysis found all CMBs (4 studies, 7223 patients, $I^2=77%$) and lobar CMBs (3 studies, 7051

Table 1. Baseline characteristics of included participants (with MRI at baseline) stratified by statin use.

Variable	All participants (N= 1693)	Statin users (N=802, 47.4%)	Non-statin users (N=891, 52.6%)
Age, years (mean, SD)	72.6 (8.4)	73.7 (7.6)	71.5 (8.9)
Female (n, %)	468 (27.6%)	166 (20.7%)	302 (33.9%)
BMI kg/m ² (mean, SD)	27.6 (4.8)	28.1 (4.7)	27.2 (4.7)
Smoking (n, %) ^a			
Never	747 (44.2%)	316 (39.4%)	431 (48.4%)
Past	817 (48.3%)	422 (52.7%)	395 (44.4%)
Current	127 (7.5%)	63 (7.9%)	64 (7.2%)
Average alcohol intake (n, %) ^b			
Low	1445 (85.4%)	686 (85.6%)	759 (85.3%)
High	246 (14.6%)	115 (14.4%)	131 (14.7%)
TCHOL mmol/L (mean, SD)	4.6 (1.1)	4.0 (0.9)	5.1 (1.0)
LDL-C mmol/L (mean, SD)	2.6 (0.9)	2.0 (0.7)	3.1 (0.9)
HDL-C mmol/L (mean, SD)	1.3 (0.4)	1.3 (0.4)	1.4 (0.4)
TRG mmol/L (median, IQR)	1.5 (1.1–2.1)	1.5 (1.1–2.0)	1.5 (1.1–2.1)
History of hypertension (n, %)	1173 (69.3%)	639 (79.7%)	534 (59.9%)
History of diabetes (n, %)	266 (15.7%)	189 (23.6%)	77 (8.6%)
Known cardiovascular disease ^c (n, %)	438 (25.9%)	356 (44.4%)	82 (9.2%)
History of stroke or TIA (n, %) ^d	337 (19.9%)	233 (29.1%)	104 (11.7%)
Use of anticoagulants (n, %)	1526 (90.1%)	739 (92.1%)	787 (88.3%)
Vitamin K Antagonist (n, %)	605 (35.7%)	330 (41.2%)	275 (30.9%)
Direct oral anticoagulation (n, %)	921 (54.4%)	409 (51.0%)	512 (57.5%)
Antiplatelets (n, %) ^e	288 (17.0%)	222 (27.8%)	66 (7.4%)
Bleeding Risk Score (mean, SD) ^f	1.83 (1.17)	2.05 (1.12)	1.63 (1.12)
Microbleeds (counts)	376	213	163
Deep (counts)	153	85	68
Lobar (counts)	237	135	102
Infratentorial (counts)	99	53	46
White matter hyperintensities volume (wmlvol)	8070.9 (11,669.25)	8773.9 (11,959.4)	7424.4 (11,364.14)
White matter hyperintensities (mean count, SD)	28.7 (23.0)	30.4 (23.5)	27.1 (22.5)

MRI: magnetic resonance imaging; BMI: Body mass index; TCHOL: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TRG: triglycerides.

^aMissing 2.

^bDefined according to the National Institute on Alcohol Abuse and Alcoholism (NIAAA); missing 2.

^cDefined as previous myocardial infarction, myocardial revascularization by surgery (by-pass), or percutaneous angioplasty; missing 1.

^dMissing 2.

^eMissing 3.

^fCalculated only for patients on anticoagulants; intermediate bleeding risk.

Table 2. Cross-sectional analyses of CMBs at baseline by statin use in patients having baseline MRI.

	Statin users (N=802)	Non-statin users (N=891)
Patients with all CMBs (n, %)	213 (26.5%)	163 (18.3%)
Multivariable adjusted OR (95% CI) ^a	1.10 (0.83–1.45)	
Patients with lobar CMBs	135 (16.8%)	102 (11.4%)
Multivariable adjusted OR (95% CI) ^a	0.94 (0.57–1.57)	

MRI: magnetic resonance imaging; CMBs: cerebral microbleeds.

^aAdjusted for sex, age, history of hypertension, smoking status, BMI, history of diabetes, history of stroke or TIA, coronary heart disease, antiplatelet use, anticoagulant use, and education.

Table 3. Longitudinal analyses of CMBs progression at follow-up by statin use in patients having baseline and follow-up MRI.

	Statin users (N=549)	Non-statin users (N=639)
CMBs progression (n, %)	44 (8.0%)	47 (7.4%)
Multivariable adjusted OR (95% CI) ^a	1.09 (0.66–1.80)	
Progression of lobar CMBs	35 (6.4%)	22 (3.4%)
Multivariable adjusted OR (95% CI) ^a	0.91 (0.14–5.93)	

MRI: magnetic resonance imaging; CMBs: cerebral microbleeds.

^aAdjusted for sex, age, history of hypertension, smoking status, BMI, history of diabetes, history of stroke or TIA, coronary heart disease, antiplatelet use, anticoagulant use, and education.

patients, $I^2=0\%$) to be inversely associated with TCHOL levels, which we did not observe.²⁵ This apparent discrepancy may be explained by the fact that three of the included studies did not take into account antiplatelet and anticoagulation drug use and none of them assessed prevalent coronary artery disease.

Very few prospective studies have investigated the association of statin use or lipid levels on CMBs progression. A subgroup analysis of a randomized controlled trial conducted in 668 geriatric stroke-free patients did not find any significant difference in the risk of new-incident CMBs, between patients treated with statins compared with placebo.¹² Statins also did not show any association with CMBs progression in patients with a history of stroke, as shown by two small prospective cohort studies.^{26,27} Our longitudinal analysis confirms these observations in a larger population. Ding et al.²⁸ conducted a prospective cohort study investigating the associations of lipid levels with CMBs progression over a 5-year follow-up in 2635 patients. A direct investigation on the association between statins and CMBs was not undertaken. The authors reported that low TRG and high HDL values were associated with a higher progression of exclusively lobar CMBs. In the present study, we explored progression of lobar CMBs in relation to statin exposure and LDL levels, not finding any

significant association, even though the absolute number of cases with CMBs progression was higher under statin users.

The proposed explanations for an increased bleeding risk under statins focus on pleiotropic side effects influencing negative platelet function and coagulation mechanisms.²⁹ Considering our population, it might be that we failed to see an association between statin use and CMBs because of altered coagulation mechanisms in patients under oral anticoagulation, though pharmacological studies have also failed to show an interaction between statins and anticoagulation in respect of bleeding tendency.³⁰

In specific contexts, CMBs have proven to serve as a marker of cerebrovascular disease that is known to increase the risk of ICH.^{31,32} The CROMIS-2 study recently showed that the presence of CMBs at baseline, after ischemic stroke due to AF, is independently associated with a higher symptomatic ICH risk in patients who start anticoagulation.³³ Other studies also identified an association between a higher burden of intracranial microhemorrhages on MRI with an increased risk for ischemic stroke, cognitive decline, and death.^{8,34} At the same time, prior investigations suggested that statin therapy might improve cardiovascular outcome in patients with AF and acute ischemic stroke.³⁵ Investigations on the overall effects of statins on

cerebrovascular small vessel disease and cognitive functions in elderly patients also tended to show a benefit of statin therapy.^{12,27} Until now, no study has been conducted investigating the associations between statin use or lipid levels with CMBs or ICH in patients with AF, a population at elevated hemorrhagic risk. Together with the current available evidence our results suggest that if indicated statin therapy should not be withheld in these patients because of fear of bleeding complications.

The major strengths of our study include the prospective part of the analysis, detailed assessment of statin use (with time-updated data), uniform MRI protocols for CMBs, MRI assessment at 2 years follow-up in a large subgroup of patients, blinded central assessment of brain imaging at baseline and follow-up, as well as assessment of CMBs location. The strengths in the analytical design include adjustment for important covariates as well as very few missing data.

The study limitations include a possible selection bias in terms of a healthy volunteer bias, since the main reason for denying participation was due to complicated study design, age/health-related issues, and lack of interest; being in accordance with the underrepresentation of older people in clinical research.^{15,36} Furthermore, in our study, the female population represented a minority (27.6%), which is compatible with more male patients suffering from AF and, therefore, reflects an AF population.^{36,37} Even if the cumulative use of anticoagulants between both groups was similar, statin users tended to have a higher use of VKA compared with DOAC. Based on prior observations suggesting a higher incidence of CMBs and ICH with VKA compared with DOAC,^{33,38} this difference might have disfavored the statin group, which, however, would still be in line with our main observation. In all, 70% of the participants with baseline MRI had also MRI at 2 years, which may imply possible bias related to availability for follow-up MRI. However, the baseline data between participants having both MRIs versus only baseline MRI were comparable. Furthermore, one-third of MRIs were performed using a 1.5 T scanner, which has a lower sensitivity to detect CMBs. However, follow-up MRI was performed using the same scanner as baseline and type of scanner was equally distributed between statin and non-statin users. In any observational study, there is a danger of residual confounding: we did not adjust for genetic factors like apoE genotype.³⁹ Finally, the low number of events accounts for low power for the outcomes of incidence of lobar CMBs and ICH. Studies with longer follow-up time and data on lobar CMBs may be necessary.

Conclusion

Statin use and lipid levels are not associated with an increased risk of CMBs in this population of patients with AF. The incidental finding of CMBs on brain imaging in

AF patients, without recent stroke or TIA, should not influence clinical decisions about statin use.

Acknowledgements

The authors thank all the participants from the Swiss-AF cohort.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Disclosures

Aujesky, Drahomir: Swiss National Science Foundation (SNF) and free drug supply from Bayer SA. **Beer, Jürg:** Swiss National Foundation of Science, the Swiss Heart Foundation (SHF), the Kardio foundation; grant support and consultancy fees to the institution from Bayer, Sanofi, and Daitchii. **Bonati, Leo:** SNF, SHF; unrestricted research grant from AstraZeneca; consultancy or advisory board fees or speaker's honoraria from Amgen, Bayer, Bristol-Myers Squibb, Claret Medical; travel grants from AstraZeneca and Bayer. **Conte, Giulio:** SNF; speaker fees from Boston Scientific, and investigator-initiated research grants from Boston Scientific. **Conen, David:** consultancy fees from Roche Diagnostics and Trimedics; speaker fees from Servier and BMS/Pfizer. **Del Giovane, Cinzia:** SNF **De Marchis, Gian Marco:** SNF, Science Funds of the University Hospital Basel, SHF, ProPatient Foundation Basel, Bangerter-Rhyner-Stiftung, Swisslife Jubiläumsstiftung for Medical Research, Swiss Neurological Society, Fondazione Dr Ettore Balli, De Quervain research grant, Thermo Fisher GmbH, Novartis grant; travel honoraria by Bayer and BMS/Pfizer; speaker honoraria by Bayer and Medtronic; consultant honoraria by Bayer and Novartis, member of the Steering Committee of PACIFIC Stroke. Industry payments are made to the research fund of the University Hospital Basel. **Fischer, Urs:** SNF and the SHF; PI of the ELAN tria; Co-PI of the DISTAL, TECNO, SWIFT DIRECT and SWITCH trial; grants from Medtronic (BEYOND SWIFT, SWIFT DIRECT), Stryker, Rapid medical, Penumbra and Phenox (DISTAL); consultancies for Medtronic, Stryker, and CSL Behring (fees paid to institution); participation in an advisory board for Alexion/Portola, Boehringer Ingelheim, Biogen and Acthera (fees paid to institution); member of a clinical event committee (CEC) of the COATING study (Phenox) and member of the data and safety monitoring committee (DSMB) of the TITAN, LATE_MT and IN EXTREMIS trials; vice-presidency of the Swiss Neurological Society. **Kastner, Peter:** employee of Roche Diagnostics, Germany. **Kühne, Michael:** personal fees from Bayer, Böhringer Ingelheim, Pfizer BMS, Daiichi Sankyo, Medtronic, Biotronik, Boston Scientific, Johnson&Johnson, Roche; grants from Bayer, Pfizer, Boston Scientific, BMS, Biotronik. **Moschovitis, Giorgio:** consultant fees for participating to advisory boards from Novartis, AstraZeneca, Bayer, and Böhringer Ingelheim. **Osswald, Stefan:** SNF, the SHF, the Foundation for CardioVascular Research Basel; grants from Roche, Bayer, Novartis, Sanofi AstraZeneca, Daiichi-Sankyo, Pfizer. **Reichlin, Tobias:** consulting honoraria or travel support from Abbott/SJM, AstraZeneca, Brahms, Bayer, Biosense-Webster, Medtronic, Pfizer-BMS and Roche (all outside of the presented work); SNF, the SHF; speaker consulting honoraria or

travel support from Abbott/SJM, AstraZeneca, Brahms, Bayer, Biosense-Webster, Biotronik, Boston-Scientific, Daiichi Sankyo, Medtronic, Pfizer-BMS and Roche; support for institution's fellowship program from Abbott/SJM, Biosense-Webster, Biotronik, Boston-Scientific and Medtronic. **Rodondi, Nicolas:** SHF. **Schwenkglens, Matthias:** SNF; grants via employment institution from Amgen, Bristol Myers & Squibb, Merck Sharp and Dohme, Novartis, Pfizer; personal fees from Amgen, Bristol Myers & Squibb, Sandoz. **All other authors:** no disclosures.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Swiss National Science Foundation (grant nos. 33CS30_148474, 33CS30_177520, 32473B_176178, 32003B_197524, and IICT 33IC30-193052) to N.R., grant of Clinical Trial Unit (CTU) of the University of Bern (grant no. 84801740) to E.M., and McMaster University Department of Medicine Mid-Career Research Award to D.C. Lipid measurements were obtained free of charge from Roche.

ORCID iDs

Elisavet Moutzouri  <https://orcid.org/0000-0002-7713-7553>

Martin Feller  <https://orcid.org/0000-0003-2519-836X>

Elisa Hennings  <https://orcid.org/0000-0003-2616-5535>

Urs Fischer  <https://orcid.org/0000-0003-0521-4051>

Supplemental material

Supplemental material for this article is available online.

References

- Sacco S, Marini C, Toni D, Olivieri L and Carolei A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. *Stroke* 2009; 40: 394–399.
- Amarenco P, Kim JS, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke. *N Engl J Med* 2020; 382: 9–19.
- Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006; 355: 549–559.
- Lin SF, Chao AC, Hu HH, et al. Low cholesterol levels increase symptomatic intracranial hemorrhage rates after intravenous thrombolysis: a multicenter cohort validation study. *J Atheroscler Thromb* 2019; 26: 513–527.
- Ribe AR, Vestergaard CH, Vestergaard M, et al. Statins and risk of intracerebral hemorrhage in individuals with a history of stroke. *Stroke* 2020; 51: 1111–1119.
- Saliba W, Rennert HS, Barnett-Griness O, Gronich N, Molad J, Rennert G and Auriel E. Association of statin use with spontaneous intracerebral hemorrhage: a cohort study. *Neurology* 2018; 91: e400–e409.
- Wu HH, Chang SH, Lee TH, Tu HT, Liu CH and Chang TY. Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants—a nationwide cohort study. *Front Cardiovasc Med* 2022; 9: 969259.
- Debette S, Schilling S, Duperron MG, Larsson SC and Markus HS. Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. *JAMA Neurol* 2019; 76: 81–94.
- Dannenberg S, Scheitz JF, Rozanski M, et al. Number of cerebral microbleeds and risk of intracerebral hemorrhage after intravenous thrombolysis. *Stroke* 2014; 45: 2900–2905.
- Marti-Fabregas J, Medrano-Martorell S, Merino E, et al. Statins do not increase markers of cerebral angiopathies in patients with cardioembolic stroke. *Sci Rep* 2018; 8: 1492.
- Wieberdink RG, Poels MM, Vernooij MW, et al. Serum lipid levels and the risk of intracerebral hemorrhage: the Rotterdam Study. *Arterioscler Thromb Vasc Biol* 2011; 31: 2982–2989.
- Ji T, Zhao Y, Wang J, et al. Effect of low-dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. *J Am Med Dir Assoc* 2018; 19: 995–1002.
- Haussen DC, Henninger N, Kumar S and Selim M. Statin use and microbleeds in patients with spontaneous intracerebral hemorrhage. *Stroke* 2012; 43: 2677–2681.
- Horstmann S, Möhlenbruch M, Wegele C, Rizos T, Laible M, Rauch G and Veltkamp R. Prevalence of atrial fibrillation and association of previous antithrombotic treatment in patients with cerebral microbleeds. *Eur J Neurol* 2015; 22: 1355–1362.
- Moutzouri E, Lyko C, Feller M, et al. Subclinical thyroid function and cardiovascular events in patients with atrial fibrillation. *Eur J Endocrinol* 2021; 185: 375–385.
- Meyre PB, Blum S, Hennings E, et al. Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing. *Eur Heart J* 2022; 43: 4899–4908.
- Conen D, Rodondi N, Mueller A, et al. Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. *Swiss Med Wkly* 2017; 147: w14467.
- Schulman S and Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost* 2005; 3: 692–694.
- Royston P and Lambert PC. *Flexible parametric survival analysis in Stata: beyond the Cox model*. Stata Press, 2011.
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014; 63: 2889–2934.
- Romero JR, Preis SR, Beiser A, et al. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study. *Stroke* 2014; 45: 1492–1494.
- Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. *Epidemiology* 2007; 18: 805–835.
- Conen D, Rodondi N, Muller A, et al. Relationships of overt and silent brain lesions with cognitive function in patients with atrial fibrillation. *J Am Coll Cardiol* 2019; 73: 989–999.
- Adam L, Feller M, Syrogiannouli L, et al. Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants. *J Thromb Haemost* 2021; 19: 931–940.

25. Feng X, Tang Q, Cheng C and Xu S. Low serum lipid levels, use of statin and cerebral microbleeds: a systematic review and meta-analysis. *J Clin Neurosci* 2021; 94: 216–225.
26. Lee SH, Lee ST, Kim BJ, Park HK, Kim CK, Jung KH and Roh JK. Dynamic temporal change of cerebral microbleeds: long-term follow-up MRI study. *PLoS ONE* 2011; 6: e25930.
27. Xiong Y, Wong A, Cavalieri M, et al. Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities. *Neurotherapeutics* 2014; 11: 606–611.
28. Ding J, Sigurdsson S, Garcia M, et al. Risk factors associated with incident cerebral microbleeds according to location in older people: the age, gene/environment susceptibility (AGES)-Reykjavik study. *JAMA Neurol* 2015; 72: 682–688.
29. Violi F, Calvieri C, Ferro D and Pignatelli P. Statins as antithrombotic drugs. *Circulation* 2013; 127: 251–257.
30. Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T and Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. *Am J Cardiovasc Drugs* 2009; 9: 59–68.
31. Charidimou A, Karayiannis C, Song TJ, et al. Brain microbleeds, anticoagulation, and hemorrhage risk: meta-analysis in stroke patients with AF. *Neurology* 2017; 89: 2317–2326.
32. Tsvigoulis G, Zand R, Katsanos AH, et al. Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden: a meta-analysis. *JAMA Neurol* 2016; 73: 675–683.
33. Wilson D, Ambler G, Shakeshaft C, et al. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. *Lancet Neurol* 2018; 17: 539–547.
34. Greenberg SM, Eng JA, Ning M, Smith EE and Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. *Stroke* 2004; 35: 1415–1420.
35. Choi KH, Seo WK, Park MS, et al. Effect of statin therapy on outcomes of patients with acute ischemic stroke and atrial fibrillation. *J Am Heart Assoc* 2019; 8: e013941.
36. Aeschbacher-Germann M, Kaiser N, Speierer A, et al. Lipid-lowering trials are not representative of patients managed in clinical practice: a systematic review and meta-analysis of exclusion criteria. *J Am Heart Assoc* 2023; 12: e026551.
37. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. *Circulation* 2014; 129: 837–847.
38. Umemura T, Mashita S and Kawamura T. Oral anticoagulant use and the development of new cerebral microbleeds in cardioembolic stroke patients with atrial fibrillation. *PLoS ONE* 2020; 15: e0238456.
39. Ingala S, Mazzai L, Sudre CH, et al. The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. *Neurobiol Aging* 2020; 95: 104–114.